Ameriprise
NERV icon

Ameriprise’s Minerva Neurosciences NERV Stock Holding History

Ameriprise’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,903
Closed -$222K – 3698
2019
Q4 		$222K Buy
+3,903
New +$172K ﹤0.01% 3554
2019
Q3 		– Sell
-2,450
Closed -$111K – 3744
2019
Q2 		$111K Buy
+2,450
New +$123K ﹤0.01% 3655

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
IVAI
Index Venture Associates IV St. Helier, Channel Islands, Jersey $6.24M AUM
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameriprise's NERV Position: Q1 2020 in Review

Ameriprise sold out of Minerva Neurosciences (NERV) in Q1 2020, closing a stake of 3,903 shares — an estimated $222K sold.

Ameriprise first reported a position in NERV in Q2 2019 and held it in 2 quarters. The position peaked at $222K in Q4 2019. 90 funds tracked by Wall St. Rank hold NERV as of Q1 2020.

  • Ameriprise reported no remaining Minerva Neurosciences position as of Q1 2020 after selling out during the quarter.
  • Ameriprise sold 3,903 Minerva Neurosciences shares in Q1 2020, an estimated $222K.
  • Ameriprise first reported a position in Minerva Neurosciences in Q2 2019 and held it in 2 quarters.
  • Ameriprise's Minerva Neurosciences position peaked at $222K in Q4 2019.
  • 90 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2020.

Based on Ameriprise's 13F filing for Q1 2020, filed 15 May 2020.